Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 9/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006670 | 0.89 | USP1 (0.40) | USP1 | |
| SCHEMBL10006887 | 0.88 | USP1 (0.37) | USP1GRIN1GRIN2BHCRTR1HCRTR2 | |
| SCHEMBL10006801 | 0.85 | ALDH1A1 (0.39) | USP1GRIN1GRIN2BMAOAMAOB | |
| SCHEMBL10006555 | 0.84 | USP1 (0.46) | USP1GRIN1GRIN2BTRIM24TSPO | |
| SCHEMBL10260978 | 0.81 | USP1 (0.39) | USP1GRIN1GRIN2B | |
| SCHEMBL10006876 | 0.79 | KDM4E (0.42) | USP1CYP2D6MAOB | |
| SCHEMBL10008025 | 0.79 | USP1 (0.40) | USP1GRIN1GRIN2BCYP2D6TSPO | |
| SCHEMBL10007126 | 0.79 | GRIN2B (0.41) | USP1GRIN1GRIN2BTSPO | |
| SCHEMBL10261033 | 0.78 | USP1 (0.43) | USP1TSPOMAOAMAOB | |
| SCHEMBL10006652 | 0.77 | USP1 (0.39) | USP1TSPOMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | USP1 1070/4885GRIN1 718/4885GRIN2B 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.